Thromboprophylaxis in patients with moderate COVID-19

Thromboprophylaxis and clinical outcomes in patients with moderate COVID-19: A comparative study - Thromboprophylaxis and clinical outcomes in patients with moderate COVID-19: A comparative study : Thromboprophylaxis in COVID-19

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000046519

Enrollment

124

Registered

2022-01-15

Start date

2021-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Enoxaparin for 3 weeks Rivaroxaban for 3 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age: from 18 to 64 years Confirmed COVID-19 infection using RT-PCR

Exclusion criteria

Exclusion criteria: History of impairment of hemostasis

Design outcomes

Primary

Measure	Time frame
(IMCU) duration, patients transferred to in (ICU),	—

Countries

Africa

Contacts

Public ContactHosam Ahmad

Egypt Ministry of Health and population Internal Medicine and biomedical chemistry

hosam.refaei@yahoo.com01000638308

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026